Coding and Reimbursement Updates
This Month’s E-Reiumbursement Newsletter from Bobbi Buell for March 31, 2026
Read More
Clinical Trial News from UC Davis
This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults.
Read More
This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Read More
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma.
Read More
Corporate Member News
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Read More
Pfizer Oncology is pleased to announce that the FDA has updated the Prescribing Information for BRAFTOVI® (encorafenib) on February 24, 2026 to include new data with an expanded indication.
Read More
Takeda, AstraZeneca, and Daiichi Sankyo, were recently highlighted in the report, "Oncology Drugs Fast-Tracked and Prioritized by the FDA in March 2026."
Read More
